Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Ansimar - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Ansimar

Approved

STANDARD

Ansimar

ABC Farmaceutici S.p.A.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: c79d617a091ebce2
Company: ABC Farmaceutici S.p.A.
Type: Standard

Approval Details

Approval Id: c79d617a091ebce2
Drug Approval Philippines Name: Ansimar
Product Name: Ansimar
Registration Number: DR-XY31275
Brand Name: Ansimar
Generic Name: Doxofylline
Dosage Form: Syrup
Dosage Strength: 100 mg/ 5 mL (2 g/100 mL)
Manufacturer: ABC Farmaceutici S.p.A.
Importer: OEP Philippines, Inc.
Distributor: Zuellig Pharma Corporation
Issuance Date: 24 January 2023
Expiry Date: 23 November 2025
Pharmacologic Category: Bronchodilator
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

c79d617a091ebce2

Type

Standard

Back to Philippines FDA Approvals